Home / For clinicians / Conditions / Pulmonology
Pulmonology: rare disease drugs and conditions
Not a doctor or health care professional? This page is for clinicians.Go to the patient version
1 condition and 2 prescribing guides so far.
By specialty and condition
Each condition page compares its drugs side by side and lists FDA decisions, label changes and open trials.
Prescribing guides
The first 90 days from the prescriber's side, built from the current label, the drugmaker's program and one public insurer policy.
Idiopathic pulmonary fibrosis (IPF)
Esbriet (pirfenidone)Liver Tests, Titration, CYP1A2 and PA CriteriaNo REMS; baseline ALT, AST and bilirubin before the first dose, a CYP1A2 medication review, smoking counseling, and prior authorization, which for brand Esbriet often means generic pirfenidone first.Jascayd (nerandomilast)Dosing With Pirfenidone, Monitoring, PANo REMS; a medication review for pirfenidone, nintedanib and CYP3A inhibitors or inducers, the Prescription and Patient Support Program Enrollment Form through CoverMyMeds or fax, and prior authorization.